Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.

The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.

A singlet oxygen scavenger includes, as an active component, hexyl diethyl amino hydroxy benzoyl benzoate, 1-(4-methoxy phenyl)-3-(4-tert-butyl phenyl)-1, 3-propanedione, terephthalylidene-3, 3′-dicamphor-10, 10′-disulfonate, 2-ethyl hexyl 4-methoxy cinnamate, or 2-ethyl hexyl 2-cyano-3, 3-diphenyl acrylate; or 2-phenyl benzimidazole-5-sulfonic acid, 4, 4′, 4″-[(1, 3, 5-triazine-2, 4, 6-triyl) tris (imino)] trisbenzoic acid tris (2-ethyl hexyl), octyl salicylate, or 3, 3, 5-trimethyl cyclohexyl salicylate; or 2-hydroxy-4-methoxy-5-(sodiooxysulfonyl) benzophenone, drometrizol trisiloxane, 2-hydroxy-4-methoxy benzophenone, or 4-methyl benzylidene camphor.

A singlet oxygen scavenger includes, as an active component, hexyl diethyl amino hydroxy benzoyl benzoate, 1-(4-methoxy phenyl)-3-(4-tert-butyl phenyl)-1, 3-propanedione, terephthalylidene-3, 3′-dicamphor-10, 10′-disulfonate, 2-ethyl hexyl 4-methoxy cinnamate, or 2-ethyl hexyl 2-cyano-3, 3-diphenyl acrylate; or 2-phenyl benzimidazole-5-sulfonic acid, 4, 4′, 4″-[(1, 3, 5-triazine-2, 4, 6-triyl) tris (imino)] trisbenzoic acid tris (2-ethyl hexyl), octyl salicylate, or 3, 3, 5-trimethyl cyclohexyl salicylate; or 2-hydroxy-4-methoxy-5-(sodiooxysulfonyl) benzophenone, drometrizol trisiloxane, 2-hydroxy-4-methoxy benzophenone, or 4-methyl benzylidene camphor.

The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.

The present invention describes the use of a NK1-antagonist, in constant combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis by providing a therapeutically effective neostigmine bromide or methylsulfate daily dose without the dose-limiting gastrointestinal adverse effects.

The present invention relates to a method of using Mebeverine as an sEH inhibitor. The present invention also provides a method of treating metabolic and cardiovascular disorders using Mebeverine.

A method of attenuating opioid induced ventilatory and/or respiratory depression and/or augmenting opioid induced analgesia in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or an adduct, a pharmaceutically acceptable salt, a tautomer, or a solvate thereof.

A method of attenuating opioid induced ventilatory and/or respiratory depression and/or augmenting opioid induced analgesia in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or an adduct, a pharmaceutically acceptable salt, a tautomer, or a solvate thereof.

The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.